Cancer treatment has long relied on surgery, chemotherapy, and immunotherapy. In recent years, scientists have also started ...
The Hearty Soul on MSN
Universal Vaccine To Treat All Cancers Is Now Enterring Human Trials
Cancer researchers have chased the idea of a universal cancer vaccine for decades. The promise sounds bold and almost ...
Background PD-1 blockade has emerged as a promising approach for functional cure of chronic hepatitis B (CHB). Objective This study aimed to evaluate the safety profile of anti-PD-1 antibody (αPD-1), ...
"Our goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer whose tumours stopped ...
Susan Galbraith, AstraZeneca’s executive vice president for oncology haematology R&D, discussed the setback in a statement. Galbraith said the goal was to “reinvigorate the immune response of patients ...
EMA validates Type II Variation marketing authorization application of Datroway as first-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy ...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY ® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...
Daiichi Sankyo and AstraZeneca have pressed swiftly to file for approval of their TROP2-targeting drug Datroway for ...
Cui, J.X., Liu, K.H. and Liang, X.J. (2026) A Brief Discussion on the Theory and Application of Artificial Intelligence in ...
Cofactor Genomics, a leader in cancer immunotherapy predictive diagnostics, today announced results from the PREDAPT non-small cell lung cancer (NSCLC) trial validating the company's OncoPrism-NSCLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback